Cardiovascular

Torcetrapib in Patients at High Risk for Coronary Events: ILLUMINATE Trial Latest Results

November 6, 2007
Philip Barter
Philip Barter
Gordon Tomaselli
Gordon Tomaselli

REFERENCE: Late Breaking Clinical Trials, Session 2, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
N Engl J Med 2007;357
PHILIP BARTER, Heart Research Institute, Sydney, Australia
COMMENT: GORDON TOMASELLI, Johns Hopkins University, Baltimore
A randomized double-blind study involving over 15,000 patients at high cardiovascular risk which looked at the new agent torcetrapib (an inhibitor of cholesteryl ester transfer protein, CETP) resulted in higher mortality in the experimental arm. The study compared torcetrapib plus atorvastatin with atorvatstin alone. Inhibition of CETP increases HDL levels and reduces LDL levels and should combat atherosclerosis. Sarah Maxwell spoke with Philip Barter who presented data on the ILLUMINATE trial at the American Heart Association meeting in Orlando.

Download this interview

Add podcast to iTunes

Similar Interviews

  • COURAGE Trial: Optimal Medical Therapy Alone is Sufficient for Patients with Stable Angina: Adding PCI Does Not Help – ILLUSTRATE Study Shows Torcetrapib Raises HDL But Fails to Lower Coronary Risk

    • STEVEN NISSEN, Cleveland Clinic, OH REFERENCE: N Engl J Med 2007 356 Reporting from: American College of Cardiolgy New Orleans Two big studies

  • Fewer Major Bleeding Events with Bivalirudin For Patients with Acute Coronary Syndromes: The ACUITY study

    • HARVEY WHITE, Auckland City Hospital, New Zealand REFERENCE: ACUITY Trial, ACC.07 Scientific Session and i2 Innovations Summit. Presentation Number: 2414-5 Patients with

  • Eicosapentaenoic Acid: Prevention of Coronary Artery Disease

    • A 20 000-person study of eicosapentaenoic acid supplements gave solid scientific support for EPA use to prevent cardiovascular events among

    Post a comment